Expert Interview
A third look at the P1 data presented at ESMO for ubamatamab, a CD3-targeting bispecific antibody under investigation for recurrent ovarian cancer
Ticker(s): REGNInstitution: St. Lukes
- Attending Physician specializing in hematology and oncology
- experience with and knowledgable about the use of bispecific antibiodies and bispecifics in development
- treats 200 patients with Diffuse Large B-Cell Lymphoma
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
